Evommune (EVMN) Gains from Sales and Divestitures (2025)
Evommune (EVMN) reported Gains from Sales and Divestitures of $109436.0 for Q4 2025.
Evommune (EVMN) Gains from Sales and Divestitures (2025) Analysis & Trends
Evommune (EVMN) has 1 years of Gains from Sales and Divestitures data on file, last reported at $109436.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $109436.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $109436.0 (changed N/A YoY), and the FY2025 annual result was $109436.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was little changed at $109436.0 in Q4 2025 per EVMN's latest filing.
- Over five years, Gains from Sales and Divestitures peaked at $109436.0 in Q4 2025 and troughed at $109436.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 109,436.00 |
| Dec 31, 2025 | 109,436.00 |